Document is current
Any future updates will be listed below
-
Authors
Knudsen, Nelson H.
Escobar, Giulia https://orcid.org/0000-0001-9177-0251
Korell, Felix
Kienka, Tamina
Nobrega, Celeste
Anderson, Seth
Cheng, Andrew Y.
Zschummel, Maria https://orcid.org/0000-0002-4778-8742
Armstrong, Alexander https://orcid.org/0009-0003-6957-9903
Bouffard, Amanda
Kann, Michael C.
Goncalves, Sadie
Pope, Hans W.
Pezeshki, Mitra
Rojas, Alexander
Suermondt, Juliette S. M. T.
Phillips, Merle
Berger, Trisha R.
Park, Sangwoo https://orcid.org/0000-0002-2701-3114
Salas-Benito, Diego
Darnell, Elijah P.
Birocchi, Filippo
Leick, Mark B. https://orcid.org/0000-0003-3111-0221
Larson, Rebecca C.
Doench, John G. https://orcid.org/0000-0002-3707-9889
Sen, Debattama https://orcid.org/0000-0002-0947-8284
Yates, Kathleen B. https://orcid.org/0000-0002-7383-5573
Manguso, Robert T. https://orcid.org/0000-0003-1336-413X
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 1 August 2025
First Online: 24 September 2025
Competing interests
: M.V.M., N.H.K., F.K., T.R.B. and R.T.M. are inventors on patents filed by MGH and the Broad Institute on these technologies. M.V.M. is an inventor on patents related to adoptive cell therapies, held by MGH (some licensed to ProMab and Luminary) and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in 2seventy bio, A2 Bio, AffyImmune, BendBio, Cargo, GBM newco, Model T bio, NexImmune and Oncternal. M.V.M. receives grant and/or research support from Kite Pharma, Moderna and Sobi. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M.’s competing interests are managed by Mass General Brigham. R.T.M. has received consulting or speaking fees from Bristol Myers Squibb, Gilead Sciences and Immunai Therapeutics, has equity ownership in OncoRev and receives research funding from Calico Life Sciences. M.B.L. is an inventor on patents related to adoptive cell therapies held by MGH and has served as a consultant for BioNTech and Cabaletta Bio. M.B.L. holds equity in AbbVie. R.C.L. is an inventor on patents related to adoptive cell therapies held by MGH, has served as a consultant for Cargo and is now an employee of Link Cell Therapies. The other authors declare no competing interests.
